BP307

General Information


DRACP ID  DRACP00472

Peptide Name   BP307

Sequence  RRLFRRILRYL

Sequence Length  11

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cell-penetrating peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
CAPAN-1 Pancreatic ductal adenocarcinoma Carcinoma IC50=35.7 ± 1.5 µM MTT assay 48 h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=64.7 ± 12.5 µM MTT assay 48 h 1

Hemolytic Activity  Human erythrocytes: 28 ± 3.2% Hemolysis=150 µM

Normal (non-cancerous) Cytotoxicity  NIH 3T3: IC50=40.0 ± 7.1 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00472

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C72H124N26O13

Absent amino acids  ACDEGHKMNPQSTVW

Common amino acids  R

Mass  174048

Pl  12.68

Basic residues  5

Acidic residues  0

Hydrophobic residues  5

Net charge  5

Boman Index  -5208

Hydrophobicity  -46.36

Aliphatic Index  141.82

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  1490

Absorbance 280nm  149

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 24480922

Title  Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties

Doi 10.1039/c3ob42422g

Year  2014

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_6842

DRACP is developed by Dr.Zheng's team.